TransMedics Group, Inc. — Director's Dealing 2023

Feb 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2023-02-27

Reporting Person: Weill David (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-27	Common Stock	M	5934	$14.20	Acquired	15934	Direct
2023-02-27	Common Stock	S	964	$77.64	Disposed	14970	Direct
2023-02-27	Common Stock	S	4970	$76.51	Disposed	10000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-27	Stock Option (Right to Buy)	$14.20	M	5934	Disposed	2030-06-04	Common Stock (5934)	Direct

Footnotes

F1: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $77.63 to $77.76, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $76.44 to $76.65, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: A Form 4 filed by the reporting person on November 14, 2022 inadvertently overstated the total number of shares held by the reporting person by 3,500 shares. The updated amounts reported here correct that error and reflect the reporting person's holdings.

F4: The option is fully vested.